If you have been reading about Angiotensin IV analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
== Editorial board memberships == Current Signal Transduction Therapy (Bentham Sci. Publisher) Editor-in-Chief Current Opinion in Molecular Therapeutics (Thomson Reuters) Journal of Receptors and Signal Transduction, (Informa Healthcare) Endocrine (Springer) International Journal of Peptide Research and Therapeutics (Springer)
Jane Shelby Richardson (born January 25, 1941) is an American biophysicist best known for developing the Richardson diagram, or ribbon diagram, a method of representing the 3D structure of proteins. Ribbon diagrams have become a standard representation of protein structures that has facilitated further investigation of protein structure and function globally. With interests in astronomy, math, physics, botany, and philosophy, Richardson took an unconventional route to establishing a science career. Richardson is a professor in biochemistry at Duke University.
In 1906, the German expedition team of Albert Grünwedel explored the Kizil Caves. Albert von Le Coq, who worked under the direction Grünwedel, had to leave in June 1906 due to health problems. Grünwedel generally photographed and copied the murals, before removing those he considered essential. Most of the fragments removed are now in Museum of Asian Art (formerly Museum für Indische Kunst) in Dahlem, Berlin. Other explorers removed some fragments of murals, that may now be found in museums in Russia, Japan, Korea and United States. Although the site has been both damaged and looted, around 5000 square metres of wall paintings remain, These murals mostly depict Jataka stories, avadanas, and legends of the Buddha, and are an artistic representation in the tradition of the Hinayana school of the Sarvastivadas. Carbon-testing and stylistical analysis helped determine three main periods in the paintings at Kizil, which cover a period from 300 CE to 650 CE. The early art of Kizil correspond to the Western school of art in the Tarim Basin, and mainly displays influences from Gandhara and the Iranian world, particularly influence from the Hephthalites, and no influence from East Asia. The Kizil Caves were designated by the Germans by a series of names, and have been separately numbered by the Chinese. A correspondence chart has been produced by Rhie. Some very early caves, now numbered 90–17 to 90–24, have been discovered since the 1990s in the lower parts of the cliff at the entrance of the central valley.
However, official IUPAC stoichiometric nomenclature is based on an idealized convention of determining the relative electronegativities of the elements by the mere virtue of their position within the periodic table. According to this convention, astatine is handled as though it is more electronegative than hydrogen, irrespective of its true electronegativity. The electron affinity of astatine, at 233 kJ mol−1, is 21% less than that of iodine. In comparison, the value of Cl (349) is 6.4% higher than F (328); Br (325) is 6.9% less than Cl; and I (295) is 9.2% less than Br. The marked reduction for at was predicted as being due to spin–orbit interactions. The first ionization energy of astatine is about 899 kJ mol−1, which continues the trend of decreasing first ionization energies down the halogen group (fluorine, 1681; chlorine, 1251; bromine, 1140; iodine, 1008).
Sources: en.wikipedia.org
=== Video games === Liches are prominent in the Might and Magic series of video games, appearing primarily as enemies, but also as playable characters in several installments. They are equally prevalent in the spin-off series Heroes of Might and Magic, where they appear in most installments as recruitable creatures, but also as heroes. One of the most prolific liches in New World Computing's old continuity was Sandro, appearing in many titles and referenced in many more. The primary antagonist of Heroes of Might and Magic III: Restoration of Erathia is also a lich: the former king of Erathia raised by necromancers. The Baldur's Gate series of video games includes several liches, as powerful but optional boss fights. Warcraft III and World of Warcraft: Wrath of the Lich King features the continent of Northrend, the realm of the eponymous Lich King and his undead minions. Arthas Menethil, also known as the Lich King, one of the most prominent antagonists in Warcraft lore, appears as a raid boss in the Wrath of the Lich King expansion, as well as a playable character in the crossover video game Heroes of the Storm. In the Dota series of video games, Lich is one of the playable heroes. In League of Legends, the champion Karthus embraced the gift of death and became a lich. In the video game Enter the Gungeon, a lich is the final boss located in Bullet Hell. In Dragon Age: The Veilguard, companion Emmrich Volkarin can become a lich.
== Interfacial potential == An interface is defined as the common boundary formed between two different phases, such as between a solid and gas. Electric potential, or charge, is the result of an object's capacity to be moved in an electric field. An interfacial potential is thus defined as a charge located at the common boundary between two phases (for example, an amino acid such as glutamate on the surface of a protein can have its side chain carboxylic acid deprotonated in environments with pH greater than 4.1 to produce a charged amino acid at the surface, which would create an interfacial potential). Interfacial potential is responsible for the formation of the electric double layer, which has a broad range of applications in what is termed electrokinetic phenomena. The development of the theory of the electric double layer is described below.
The Barnett Ministry was the 35th Ministry of the Government of Western Australia. It included 13 members of the Liberal Party, three members of the National Party and an independent. It was led by the Premier of Western Australia, Colin Barnett, and Deputy Premier Liza Harvey. It succeeded the Carpenter Ministry on 23 September 2008 following the 2008 election and was succeeded by the First McGowan Ministry following the Liberal Party's defeat at the 2017 election.
Sources: en.wikipedia.org
=== Other uses in science and technology === Gene-specific tag (also referred to as SNP) General set theory General strain theory, in sociology General systems theory Generalized structure tensor Global surface temperature Glutathione S-transferase, an enzyme family Goode Solar Telescope, in California
Crick's period at Cambridge was the pinnacle of his long scientific career, but he left Cambridge in 1977 after 30 years, having been offered (and having refused) the Mastership of Gonville and Caius. James Watson claimed at a Cambridge conference marking the 50th anniversary of the discovery of the structure of DNA in 2003:
Macallum, A.B. & Collop (sic), J.B. (1914), "A New Substance in Nerve Cells" (read: Monday, 15 September 1913), Report of the Eighty-Third Meeting of the British Association for the Advancement of Science: Birmingham: 1913: September 10-17 (Physiology Section), pp. 673–674. Marier, Virginie & Piper, Tina (2010), "Early Twentieth-Century Canadian Medical Patent Law in Practice: James Bertram Collip and the Discovery of Emenin", University of Toronto Law Journal, Vol.60, No.3, (Summer 2010), pp. 855-892. US patent no.1,469,994 (held by "Frederick G. Banting and Charles Herbert Best, of Toronto, Ontario, and James Bertram Collip of Edmonton, Alberta, Canada"), (filed: 12 January 1923), (patented: 9 October 1923), for "Extract Obtainable from the Mammalian Pancreas or from the Related Glands in Fishes, Useful in the Treatment of Diabetes Mellitus, and a Method of Preparing it".
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.